Last reviewed · How we verify
Bimatoprost 0.03% sterile solution
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension, Hypotrichosis of the eyelashes.
At a glance
| Generic name | Bimatoprost 0.03% sterile solution |
|---|---|
| Also known as | LUMIGAN® |
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
- Hypotrichosis of the eyelashes
Common side effects
- Conjunctival hyperemia (redness)
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose (PHASE4)
- Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children (PHASE4)
- Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence (PHASE3)
- Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis (PHASE4)
- Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |